Searchable abstracts of presentations at key conferences in endocrinology

ea0016p721 | Thyroid | ECE2008

Clinical impact of positron emission tomography/computed tomography in the follow-up of well differentiated thyroid carcinoma with elevated anti-thyroglobuline auto-antibodies

Zerdoud Slimane , Dierickx Lawrence , Benlyazid Adil , Sarini Jerome , Dahimene Samir , Bastie Delphine , Bennet Antoine , Courbon Frederic , Caron Philippe

Aim: Assessment of the clinical impact of a positron emission tomography/computed tomography (PET/CT) with FDG in the management of differentiated thyroid cancer (DTC) in patients with increased or positive thyroglobulin autoantibodies (AbTg).Methodology: Retrospective study involving 15 patients seen in the follow-up with confirmed DTC primarily treated with total thyroidectomy and Iodine 131. Patients presenting with increased AbTg and a negative or no...

ea0060oc2 | (1) | UKINETS2018

Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study

Prasad Vikas , Srirajaskanthan Raj , Toumpanakis Christos , Grana Chiara Maria , Baldari Sergio , Shah Tahir , Lamarca Angela , Courbon Frederic , Scheidhauer Klemens , Baudin Eric , Thanh Xuan Mai Truong , Houchard Aude , Bodei Lisa

Background: PRRT, licensed for gastroenteropancreatic (GEP) NETs, has been used with somatostatin analogues such as lanreotide autogel (LAN). PRELUDE is the first international, multicentre retrospective study, with central radiology reading, to describe use of LAN with PRRT (LAN-PRRT) in advanced NETs.Methods: PRELUDE (NCT02788578) was an international, retrospective, non-comparative analysis of medical records of patients receiving LAN with 177Lu-DOTAT...